Radiation, Immunotherapy, and Targeted Therapy Before Lung Cancer Surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You should be able to do most daily activities on your own (performance status 0 or 1).
- Your lung cancer must be stage IB to IIIB (T3-4N2) and can be removed with surgery.
- Your cancer must not have a specific gene change called EGFR mutation or ALK fusion.
- You cannot have another active cancer or a history of other cancer in the last 3 years.
- You must not have an active autoimmune disease, a lung condition called interstitial lung disease, or be taking strong immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Hear when a new Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.